论文部分内容阅读
抗体-药物偶联物(Antibody-drug conjugates,ADCs)由“弹头”药物(细胞毒药物)、抗体以及偶联抗体和药物的偶联链3部分组成,其作为1种新型药物,结合了抗体的靶向特异性和小分子药物的细胞毒作用,已成为当今肿瘤研究领域的热点。根据其细胞毒药物来源可分为陆地与海洋两大类,本文总结了近年来这两大类抗体偶联药物的研究进展,并从靶点的特异性、抗体的亲和力、高效的细胞毒分子及合适的偶联链等方面对ADCs的发展关键进行了简要评述。
Antibody-drug conjugates (ADCs) consist of 3 parts of the coupled chain of antibodies and antibodies and drug conjugates, as a novel drug, Targeted antibody specificity and small molecule drug cytotoxicity, has become the hot spot in the field of cancer research. According to its origin of cytotoxic drugs can be divided into two major categories of land and sea, this paper summarizes the two major types of antibody conjugate drugs in recent years, research progress, and from the target specificity, antibody affinity, efficient cytotoxic molecules And the appropriate coupling chains and other aspects of the key to the development of ADCs briefly reviewed.